Abstract:
:Chronic hepatitis C (CHC) affects over 185 million individuals worldwide, approximately 3% of the world's population. CHC can lead to quality of life impairment, cirrhosis, hepatocellular carcinoma (HCC), liver failure and liver-related death. While CHC has been associated with increases in HCC, liver-related mortality and all-cause mortality, being cured of CHC is associated with improvement in these outcomes. Older interferon-based regimens were complex and toxic and required 6-12 months of therapy, with cure rates averaging around 40-45% for HCV genotype 1. Newer interferon-free regimens are now available in the US, Europe, Japan and in other countries. These regimens have short durations, minimal side effects, low pill burden and efficacy approaching 90-100%. We may eventually see single-tablet regimens lasting no more than 4-6 weeks. This review will summarize the data regarding these interferon-free regimens, including Gilead's Harvoni (sofosbuvir/ledipasvir), AbbVie's Viekira Pak (paritaprevir/ritonavir/ombitasvir with dasabuvir), and Janssen's Olysio (simeprevir) with sofosbuvir. Some practical considerations as we move into an interferon-free era will also be discussed, such as patient adherence and drug-drug interactions.
journal_name
Therap Adv Gastroenteroljournal_title
Therapeutic advances in gastroenterologyauthors
Lam BP,Jeffers T,Younoszai Z,Fazel Y,Younossi ZMdoi
10.1177/1756283X15587481subject
Has Abstractpub_date
2015-09-01 00:00:00pages
298-312issue
5eissn
1756-283Xissn
1756-2848pii
10.1177_1756283X15587481journal_volume
8pub_type
杂志文章,评审abstract::Helicobacter pylori (H. pylori) are gram-negative bacteria that selectively colonizes the gastric mucosa. The prevalence of H. pylori infection varies from 20 to 50% in industrialized countries to over 80% in developing countries. The infection may persist lifelong without specific treatment. Prolonged infection and i...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X08094880
更新日期:2008-09-01 00:00:00
abstract:Background:The incidence of Clostridioides difficile infection (CDI) is increasing in the general population. Data on the epidemiology of CDI in peripartum women - a highly vulnerable patient population - is scarce. The objective of this study was to report the incidence of CDI in peripartum women. Methods:A single-ce...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284820942621
更新日期:2020-07-27 00:00:00
abstract:Objective:i-Scan is a digital image enhancement technology, reported to improve diagnostic performance during endoscopy. Previous studies have investigated the accuracy of i-scan for distinguishing between neoplastic and non-neoplastic colonic polyps and suggested diagnostic accuracy close to that required for use in r...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284818814948
更新日期:2018-12-06 00:00:00
abstract::In this article we provide a contemporary overview of available clinical data on certolizumab pegol, a pegylated anti-tumor necrosis factor (TNF) alpha agent that comprises a uniquely small protein, and its emerging role as a therapy for Crohn's disease (CD). The results from a comprehensive clinical trial program sug...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X11413315
更新日期:2011-11-01 00:00:00
abstract:Background:Vedolizumab (VDZ) is a gut-specific α4-β7 integrin antagonist that has demonstrated efficacy in Crohn's disease (CD) and ulcerative colitis (UC). The safety of VDZ in the perioperative period remains unclear. The aim of this study was to evaluate postoperative complications and perioperative safety in VDZ-tr...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284818783614
更新日期:2018-06-21 00:00:00
abstract:Background:The environment surrounding Helicobacter pylori eradication treatment is dramatically changing. Recently, vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), was introduced onto the market in 2015. The aging of Japan's demographic structure is becoming pronounced. In this study, we exami...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284819858511
更新日期:2019-07-04 00:00:00
abstract::Malignant tumor cells are equipped with mechanisms that can help them escape the surveillance by host immune system. Immune checkpoint molecules can transduce coinhibitory signals to immunocompetent cells and exert immunosuppressive roles in antitumor immunity. Programmed death-1 (PD-1) and programmed death ligand-1 (...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X16658251
更新日期:2016-11-01 00:00:00
abstract:BACKGROUND:Some chronic hepatitis C virus (HCV), genotype 1 infected patients treated with direct antiviral agents (DAAs) remain viremic at end of treatment (EOT+), yet go on to achieve sustained virological response 12 weeks after completion of therapy (SVR12). The incidence of EOT+/SVR in patients with genotype 1 and...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X16672392
更新日期:2017-01-01 00:00:00
abstract::Atrial fibrillation (AF) is the most common arrhythmia worldwide and is associated with significant morbidity and mortality. A number of risk factors have been associated with AF, though few studies have explored the association between gastrointestinal and liver diseases and AF. Additionally, AF and treatment for AF ...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284819832237
更新日期:2019-04-02 00:00:00
abstract::Erratum to 'Possible interactions between dietary fibres and 5-aminosalicyclic acid' by C Henriksen, S Hansen, I Nordgaard-Lassen, J Rikardt Anderson and P Madsen. Therapeutic Advances in Gastroenterology (2010) 3(1) 5-9 [DOI: 10.1177/ 1756283X09347810][This corrects the article on p. 5 in vol. 3.]. ...
journal_title:Therapeutic advances in gastroenterology
pub_type: 已发布勘误
doi:10.1177/1756283X10363751
更新日期:2012-09-01 00:00:00
abstract::In 2010, four independent groups almost simultaneously reported the association of the novel interleukin-1 (IL-1) family member, IL-33, with inflammatory bowel disease (IBD). The findings were remarkably consistent and demonstrated that IL-33 is markedly upregulated in, and specific to, ulcerative colitis (UC). In add...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X11410770
更新日期:2011-09-01 00:00:00
abstract:BACKGROUND:Self-expandable metal stent (SEMS) placement is a minimally invasive treatment for palliation of malignant colorectal strictures and as a bridge to surgery. However, the use of SEMS for benign colorectal diseases is controversial. The purpose of this retrospective study is to evaluate the efficacy and safety...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X15610052
更新日期:2016-03-01 00:00:00
abstract:Background:Postoperative pancreatic collection (POPC) is a frequent complication after pancreatectomy. Although percutaneous drainage (PD) has been the treatment of choice for POPC with encapsulation, endoscopic ultrasound-guided transmural drainage (EUS-TD) was recently reported effective for this condition. The main ...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284819884418
更新日期:2019-10-24 00:00:00
abstract:METHODS:Suboptimal bowel preparation, present in over 20% of colonoscopies, can severely compromise the effectiveness of the colonoscopy procedure. We surveyed 93 primarily urban minority men and women who underwent asymptomatic 'screening' colonoscopy regarding their precolonoscopy bowel-preparation experience. RESUL...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X13498661
更新日期:2013-11-01 00:00:00
abstract::Functional gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia, are complex conditions with multiple factors contributing to their pathophysiology. As a consequence they are difficult to treat and have posed significant challenges to the pharmaceutical industry when trying to develop ...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X10369922
更新日期:2010-09-01 00:00:00
abstract:BACKGROUND:Diarrhea-predominant irritable bowel syndrome (IBS-D) impairs patient quality of life (QOL). Rifaximin is an oral, nonsystemic antibiotic indicated for IBS-D. The objective of this secondary analysis was to evaluate rifaximin retreatment on IBS-related QOL in patients with IBS-D. METHODS:Patients received o...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X17726087
更新日期:2017-09-01 00:00:00
abstract:BACKGROUND:Endoscopic therapy for early neoplasia in Barrett's esophagus (BE) is evolving. Endoscopic resection has an increasing role. We wanted to evaluate the safety and efficacy of multi-band ligation/resection [ER-L] without pre-injection in BE with high-grade dysplasia [HGD] and intramucosal carcinoma [IMCA]. ME...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X09346794
更新日期:2009-11-01 00:00:00
abstract::Portal hypertension represents one of the major clinical consequences of chronic liver disease, having a deep impact on patients' prognosis and survival. Its pathophysiology defines a pathological increase in the intrahepatic vascular resistance as the primary factor in its development, being subsequently aggravated b...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284818811294
更新日期:2018-11-25 00:00:00
abstract::Endoscopic argon plasma coagulation and bipolar electrocautery are currently preferred treatments for chronic radiation proctitis, but ulcerations and strictures frequently occur. Radiofrequency ablation (RFA) has been successful for mucosal ablation in the esophagus. Here we report the efficacy of RFA with the BarRx ...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283x08103341
更新日期:2009-01-01 00:00:00
abstract:Aims:Gastric cancer (GC) is the third leading cause of cancer death worldwide, but the burden of disease is not distributed evenly. GC screening routinely occurs in some high-incidence regions/countries and is generally cost-effective, which is attributed largely to the associated GC mortality reduction. In regions of ...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284820941662
更新日期:2020-07-16 00:00:00
abstract:Background:Variability in glucagon-like peptide (GLP)-1 and GLP-2 plasma concentrations has been suggested in Celiac disease (CD), with inconclusive results. We assessed the association between serum levels of GLP-1 and GLP-2 and their duodenal receptor expression in children with and without CD. Methods:This was a tw...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284819842756
更新日期:2019-04-17 00:00:00
abstract::In recent years, mucosal healing has emerged as a key therapeutic goal in the clinical management of patients with Crohn's disease, as it has been associated with improved long-term clinical outcomes. With the vast improvements in endoscopic imaging techniques and the increase in available treatment options, which rep...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284819856865
更新日期:2019-06-14 00:00:00
abstract::On 31 December 2019, the WHO China Country Office was informed of cases of pneumonia of unknown etiology detected in Wuhan (Hubei Province of China). In January 2020, a new coronavirus named SARS-CoV2 was isolated and, since that time, SARS-CoV2 related disease (COVID-19) rapidly spread all over the world becoming pan...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284820935187
更新日期:2020-06-24 00:00:00
abstract:Background:One in four patients with primary Clostridioides difficile infection (CDI) develops recurrent CDI (rCDI). With every recurrence, the chance of a subsequent CDI episode increases. Early identification of patients at risk for rCDI might help doctors to guide treatment. The aim of this study was to externally v...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284820977385
更新日期:2021-01-09 00:00:00
abstract:Background:The clinical outcome of patients with obscure gastrointestinal bleeding (OGIB) during antithrombotic drug therapy has not been fully investigated. Methods:Patients who underwent video capsule endoscopy (VCE) for the investigation of OGIB at Okayama University Hospital from January 2009 to March 2016 were en...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X17746930
更新日期:2018-01-14 00:00:00
abstract:Background and Aims:Efficacy of adalimumab in Crohn's disease (CD) has not been shown in China. The aim of this study was to evaluate the efficacy and safety of adalimumab in Chinese patients with CD. Methods:This 26-week, multicenter, phase III study evaluated patients with moderately to severely active CD and elevat...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284820938960
更新日期:2020-07-16 00:00:00
abstract::Gut microbiota is a compilation of microorganisms dwelling in the entire mammalian gastrointestinal tract. They display a symbiotic relationship with the host contributing to its intestinal health and disease. Even a slight fluctuation in this equipoise may be deleterious to the host, leading to many pathological cond...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X12454590
更新日期:2013-01-01 00:00:00
abstract:Background:Recently the American Society for Gastrointestinal Endoscopy addressed the 'resect and discard' strategy, determining that accurate in vivo differentiation of colorectal polyps (CP) is necessary. Previous studies have suggested a promising application of artificial intelligence (AI), using deep learning in o...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284820910659
更新日期:2020-03-20 00:00:00
abstract::Chronic hepatitis C virus (HCV) infection is a leading cause of chronic liver diseases and hepatocellular carcinoma (HCC) worldwide. In the past few years, anti-HCV therapies have undergone a revolution with the approval of multiple direct-acting antivirals (DAAs), which enable interferon-free treatments with consider...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284818759483
更新日期:2018-03-21 00:00:00
abstract::Hepatocellular carcinoma (HCC) is a common and serious health problem with high mortality. Treatment for HCC remains largely unsatisfactory owing to its high recurrence rates and frequent accompanying cirrhosis. In addition, the unique immune environment of the liver promotes tolerance, which, in conjunction with immu...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X17722061
更新日期:2017-10-01 00:00:00